Jazz Pharmaceuticals PLC (JAZZ) Receives $182.71 Average Target Price from Analysts

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have received a consensus rating of “Buy” from the twenty-two analysts that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $182.71.

A number of analysts have issued reports on the stock. BidaskClub cut shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. ValuEngine cut shares of Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 18th. Zacks Investment Research upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $158.00 target price for the company in a research note on Tuesday, April 16th. Mizuho reiterated a “hold” rating and issued a $147.00 target price (up from $137.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $185.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, March 26th.

In related news, SVP Paul Treacy sold 874 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $139.50, for a total transaction of $121,923.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Suzanne Sawochka Hooper sold 6,666 shares of the business’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total transaction of $933,240.00. Following the transaction, the executive vice president now directly owns 40,401 shares in the company, valued at approximately $5,656,140. The disclosure for this sale can be found here. Insiders sold 11,668 shares of company stock valued at $1,606,567 over the last 90 days. 3.90% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. Signition LP increased its position in Jazz Pharmaceuticals by 8.6% during the first quarter. Signition LP now owns 9,417 shares of the specialty pharmaceutical company’s stock worth $1,346,000 after acquiring an additional 747 shares during the period. Wedge Capital Management L L P NC bought a new position in Jazz Pharmaceuticals during the first quarter worth $40,947,000. Aviance Capital Partners LLC increased its position in Jazz Pharmaceuticals by 4.3% during the first quarter. Aviance Capital Partners LLC now owns 14,365 shares of the specialty pharmaceutical company’s stock worth $2,053,000 after acquiring an additional 587 shares during the period. Rice Hall James & Associates LLC increased its position in Jazz Pharmaceuticals by 3.1% during the first quarter. Rice Hall James & Associates LLC now owns 42,835 shares of the specialty pharmaceutical company’s stock worth $6,123,000 after acquiring an additional 1,301 shares during the period. Finally, Renaissance Group LLC increased its position in Jazz Pharmaceuticals by 3.8% during the first quarter. Renaissance Group LLC now owns 109,421 shares of the specialty pharmaceutical company’s stock worth $15,642,000 after acquiring an additional 3,983 shares during the period. 92.88% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ JAZZ opened at $129.57 on Tuesday. The company has a quick ratio of 3.42, a current ratio of 3.57 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $7.34 billion, a price-to-earnings ratio of 10.59, a price-to-earnings-growth ratio of 1.06 and a beta of 1.16. Jazz Pharmaceuticals has a 12-month low of $113.52 and a 12-month high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.61. The firm had revenue of $476.46 million during the quarter, compared to analysts’ expectations of $459.48 million. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. The company’s revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.95 earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals will post 13.19 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: Analyst Ratings Trading

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit